Jennifer Llewelyn - Diffusion Pharmaceuticals Director CMC
Insider
Jennifer Llewelyn is Director CMC of Diffusion Pharmaceuticals
| Phone | 434 220 0718 |
| Web | https://www.diffusionpharma.com |
Diffusion Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3824) % which means that it has lost $0.3824 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6396) %, meaning that it created substantial loss on money invested by shareholders. Diffusion Pharmaceuticals' management efficiency ratios could be used to measure how well Diffusion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Diffusion Pharmaceuticals currently holds 67.89 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Diffusion Pharmaceuticals has a current ratio of 11.36, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Diffusion Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Torsten Hombeck | Akari Therapeutics PLC | 55 | |
| Lisa Middlebrook | iBio, Common Stock | N/A | |
| Eduardo Marbn | Capricor Therapeutics | N/A | |
| MBA MD | Monopar Therapeutics | 38 | |
| Margaret MD | Pulmatrix | 67 | |
| Seth MD | Tonix Pharmaceuticals Holding | 67 | |
| CPA CPA | NextCure | 61 | |
| Miles Nunn | Akari Therapeutics PLC | 56 | |
| , MBA | Soleno Therapeutics | N/A | |
| Xavier Avat | Capricor Therapeutics | N/A | |
| Anthony MBA | Capricor Therapeutics | 39 | |
| David Sesin | Jaguar Animal Health | N/A | |
| Thomas III | iBio, Common Stock | 57 | |
| Randy Maddux | iBio, Common Stock | 63 | |
| Aidan Curran | Pulmatrix | N/A | |
| Michael MSBA | NextCure | 64 | |
| Ray MD | Akari Therapeutics PLC | 79 | |
| Shane Lea | Cellectar Biosciences | N/A | |
| Anish MD | Soleno Therapeutics | 55 | |
| CPA CPA | Cellectar Biosciences | 60 | |
| Nancy Hecox | Tenax Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.64 | |||
| Return On Asset | -0.38 |
Diffusion Pharmaceuticals Leadership Team
Elected by the shareholders, the Diffusion Pharmaceuticals' board of directors comprises two types of representatives: Diffusion Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Diffusion. The board's role is to monitor Diffusion Pharmaceuticals' management team and ensure that shareholders' interests are well served. Diffusion Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Diffusion Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dr Cobuzzi, CEO Pres | ||
| Suzanne Cassidy, Director Assurance | ||
| Jennifer Llewelyn, Director CMC | ||
| Christopher MD, Chief Officer | ||
| Harry Cook, VP Operations | ||
| Kelly Hoy, Director Management | ||
| William JD, Gen Sec | ||
| Raven MS, Chief Officer | ||
| David MD, Chief Medical Officer and Member of Scientific Advisory Board | ||
| William Hornung, Chief Officer |
Diffusion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Diffusion Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | |||
| Return On Asset | -0.38 | |||
| Current Valuation | (6.02 M) | |||
| Shares Outstanding | 2.04 M | |||
| Shares Owned By Insiders | 0.23 % | |||
| Shares Owned By Institutions | 10.27 % | |||
| Number Of Shares Shorted | 2.54 K | |||
| Price To Earning | (0.60) X | |||
| Price To Book | 0.51 X | |||
| EBITDA | (15.97 M) |
Pair Trading with Diffusion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Diffusion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Diffusion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Dell Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dell Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dell Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dell Technologies to buy it.
The correlation of Dell Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dell Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dell Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dell Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Diffusion Stock
If you are still planning to invest in Diffusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Diffusion Pharmaceuticals' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |